Article
Full Access
Impaired mobility of human t lymphocyte surface molecules during inactive systemic lupus erythematosus. relationship to a defective camp pathway
Gary M. Kammer MD,
Elizabeth Mitchell BS,
Corresponding Author
Gary M. Kammer MD
Associate Professor of Medicine
Division of Rheumatic Diseases, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Address reprints requests to Gary M. Kammer, MD, Department of Medicine, 2074 Abington Road, Cleveland, OH 44106Search for more papers by this authorElizabeth Mitchell BS
Medical Student
Division of Rheumatic Diseases, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Search for more papers by this authorGary M. Kammer MD,
Elizabeth Mitchell BS,
Corresponding Author
Gary M. Kammer MD
Associate Professor of Medicine
Division of Rheumatic Diseases, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Address reprints requests to Gary M. Kammer, MD, Department of Medicine, 2074 Abington Road, Cleveland, OH 44106Search for more papers by this authorElizabeth Mitchell BS
Medical Student
Division of Rheumatic Diseases, Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Search for more papers by this authorAbstract
The T lymphocytes of patients with active systemic lupus erythematosus (SLE) exhibit impaired capping of the surface molecules CD3, CD4, and CD8 and a defective cAMP-dependent pathway. Since the mobility of these molecules is regulated in part by cAMP, we sought to determine whether there is a specific defect(s) along the T cell cAMP pathway that contributes to the persistent capping disorder observed during inactive SLE. The data suggest that a defect may exist at the level of cAMP-dependent protein kinase activation or at a point distally. We propose that a disorder of cAMP-dependent protein kinase activity might account for the defect of capping observed in both the CD3, CD4 (helper/inducer) and CD3,CD8 (suppressor) subsets observed in SLE.
Reference
- 1 Schur PH: The Clinical Management of Systemic Lupus Erythematosus. New York, Grune & Stratton, 1983
- 2 Budman DR, Merchant EB, Steinberg AD, Doft B, Gershwin ME, Lizzio E, Reeves JP: Increased spontaneous activity of antibody-forming cells in the peripheral blood of patients with active SLE. Arthritis Rheum 20: 829–833, 1977
- 3 Sakane T, Steinberg AD, Green I: Failure of autologous mixed lymphocyte reactions between T- and non-T-cells in patients with systemic lupus erythematosus. Proc Natl Acad Sci USA 75: 3464–3468, 1978
- 4 Gottlieb AB, Lahita RG, Chiorazzi N, Kunkel HG: Immune function in systemic lupus erythematosus: impairment of in vitro T-cell proliferation and in vivo antibody response to exogenous antigen. J Clin Invest 63: 885–892, 1979
- 5 Hoffman T: Natural killer function in systemic lupus erythematosus. Arthritis Rheum 23: 30–35, 1980
- 6 Alcocer-Varela J, Alarcon-Segovia D: Decreased production of and response to interleukin 2 by cultured lymphocytes from patients with systemic lupus erythematosus. J Clin Invest 69: 1388–1392, 1982
- 7 Mandler R, Birch RE, Polmar SH, Kammer GM, Rudolph SA: Abnormal adenosine-induced immunosuppression and cAMP metabolism in T lymphocytes of patients with systemic lupus erythematosus. Proc Natl Acad Sci USA 79: 7542–7546, 1982
- 8 Kammer GM, Birch RE, Polmar SH: Impaired immunoregulation in systemic lupus erythematosus: defective adenosine-induced suppressor T lymphocyte generation. J Immunol 130: 1706–1712, 1983
- 9 Linker-Israeli M, Bakke AC, Ketridon RC, Gendler S, Gillis S, Horwitz DA: Defective production of interleukin 1 and interleukin 2 in patients with systemic lupus erythematosus. J Immunol 130: 2651–2655, 1983
- 10 Sibbitt WL Jr, Likar L, Spellman CW, Bankhurst AD: Impaired natural killer cell function in systemic lupus erythematosus: relationship to interleukin-2 production. Arthritis Rheum 26: 1316–1320, 1983
- 11 Hirose T, Hara M, Kitani A, Hirose W, Noriokoy K, Kawagoe M, Nakamura H: Abnormal production of and response to B cell growth factor and B cell differentiation factor in patients with systemic lupus erythematosus. Scand J Immunol 21: 141–150, 1985
- 12 Sagawa A, Abdou NI: Suppressor-cell dysfunction in systemic lupus erythematosus: cells involved and in vitro correction. J Clin Invest 62: 789–796, 1978
- 13 Gladman D, Keystone E, Urowitz M, Cane D, Poplonski L: Impaired antigen-specific suppressor cell activity in patients with systemic lupus erythematosus. Clin Exp Immunol 40: 77–82, 1980
- 14 Delfraissy JF, Segond P, Galanaud P, Wallon C, Massias P, Dormont J: Depressed primary in vitro antibody response in untreated systemic lupus erythematosus: T helper cell defect and lack of defective suppressor cell function. J Clin Invest 66: 141–148, 1980
- 15 Okudaira K, Searles RP, Goodwin JS, William RC Jr: Antibodies in the sera of patients with systemic lupus erythematosus that block the binding of monoclonal-la to la-positive targets also inhibit the autologous mixed lymphocyte response. J Immunol 129: 582–586, 1982
- 16 Goldschmidt LP, Kresina TF, Kammer GM: Effect of anti-T cell autoantibodies from systemic lupus erythematosus sera upon T lymphocyte functions. Arthritis Rheum 29: 646–654, 1986
- 17 Taurog JD, Raveche ES, Smathers PA, Glimcher LH, Huston DP, Hansen CT, Steinberg AD: T cell abnormalities in NZB mice occur independently of autoantibody production. J Exp Med 153: 221–234, 1981
- 18 Bocchieri MH, Riblet RJ, Smith JB: Autologous mixed lymphocyte reactions in NZB mice: analysis in recombinant inbred lines shows a T cell defect unrelated to autoantibody production. Eur J Immunol 11: 159–162, 1981
- 19 Kammer GM, Smith JA, Mitchell R: Capping of human T cell specific determinants: kinetics of capping and receptor re-expression and regulation by the cytoskeleton. J Immunol 130: 38–44, 1983
- 20 Kammer GM, Rudolph SA: Regulation of human T lymphocyte surface antigen mobility by a purinergic receptor. J Immunol 133: 3298–3352, 1984
- 21 Kammer GM, Boehm CA: Regulation of human T lymphocyte surface antigen mobility by a cAMP-dependent pathway. Submitted for publication
- 22 Kammer GM, Boehm CA, Rudolph SA: Role of adenylate cyclase on human T-lymphocyte surface antigen capping. Cell Immunol 101: 251–258, 1986
- 23 Kammer GM: Impaired T cell capping and receptor regeneration in active systemic lupus erythematosus: evidence for a disorder intrinsic to the T lymphocyte. J Clin Invest 72: 1686–1697, 1983
- 24 Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25: 1271–1277, 1982
- 25 Ropes, MW, Bennett GA, Cobb S, Jacox R, Jessar RA: 1958 revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 9: 175–176, 1958
- 26 Sheppard H, Wiggan G: Analogues of 4-(3, 4-dimethoxybenzyl)-2-imidazolidinone as potent inhibitor of rat erythrocyte adenosine cyclic 3',5'-phosphate phosphodiesterase. Mol Pharmacol 7: 111–115, 1970
- 27 Pomerantz AH, Rudolph SA, Haly BE, Greengard P: Photoaffinity labeling of a protein kinase from bovine brain with 8-azido-adenosine 3',5'-monophosphate. Biochemistry 14: 3858–3862, 1975
- 28 Krebs EG, Beavo JA: Phosphorylation-dephosphorylation of enzymes. Annu Rev Biochem 48: 923–959, 1979
- 29 Goffstein B, Gordon LK, Wedner HJ, Atkinson JP: Cyclic AMP concentrations in human peripheral blood lymphocytes. J Lab Clin Med 96: 1002–1014, 1980
- 30 Seamon KB, Padgett W, Daly JW: Forskolin: unique diterpine activator of adenylate cyclase in membranes and in intact cells. Proc Natl Acad Sci USA 78: 3363–3367, 1981
- 31 Nagamine Y, Reich E: Gene expression and cAMP. Proc Natl Acad Sci USA 82: 4606–4610, 1985
- 32 Schultz LA, Kammer GM, Rudolph SA: Characterization of the human T lymphocyte adenosine receptor: comparison of normal and systemic lupus erythematosus. FASEB J (in press)
